Advertisement
UK markets close in 5 hours 47 minutes
  • FTSE 100

    7,827.04
    -50.01 (-0.63%)
     
  • FTSE 250

    19,272.58
    -178.09 (-0.92%)
     
  • AIM

    740.93
    -4.36 (-0.59%)
     
  • GBP/EUR

    1.1680
    -0.0003 (-0.03%)
     
  • GBP/USD

    1.2451
    +0.0012 (+0.10%)
     
  • Bitcoin GBP

    51,963.58
    +2,593.26 (+5.25%)
     
  • CMC Crypto 200

    1,333.45
    +20.83 (+1.61%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.19
    +0.46 (+0.56%)
     
  • GOLD FUTURES

    2,395.40
    -2.60 (-0.11%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,692.83
    -144.57 (-0.81%)
     
  • CAC 40

    7,973.57
    -49.69 (-0.62%)
     

Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.